Asad Taherbhoy
Director, Drug Discovery, Foghorn Therapeutics Inc.
Asad Taherbhoy is listed as Director, Drug Discovery, Foghorn Therapeutics Inc.. B2DB records 2 sessions at 1 conference in 2026, most recently Drug Discovery Chemistry Europe 2026 (November 2026). Speaks mainly at Hospitals and Health Care events.
Compiled from published conference agendas; not yet confirmed by Asad. Is this you? Claim this profile.
- Sector: Hospitals and Health Care
About
Asad Taherbhoy is Senior Director of Discovery at Foghorn Therapeutics, where he leads platform and project teams focused on targeting chromatin remodeling mechanisms using diverse small molecule modalities, including enzyme and PPI inhibition, targeted protein degradation, and induced proximity. Previously, Asad worked on E3 ligase-focused drug discovery at Nurix. He completed his postdoctoral training at Genentech and earned his PhD at St. Jude Children’s Research Hospital with Brenda Schulman, studying the ubiquitin pathway.
Sessions at 1 conference
Drug Discovery Chemistry Europe 2026 11 November 2026 – 12 November 2026
- Designing and Optimizing Molecular Glues and Proximity-based Drugs Moderator · 11 November 2026
- Rewiring Transcription via Induced Proximity Speaker · 11 November 2026
Spoke alongside
People who have shared a session with Asad at events on B2DB.
- Gopal Sapkota Professor · University of Dundee 1 shared session